Ketamine extended release(Douglas Pharmaceuticals)

N/A

Report date: 2025/10/24 17:59:42

Base Information

Drug NameKetamine extended release(Douglas Pharmaceuticals)
Drug Alias NameR-107
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, Treatment-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDouglas Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Treatment-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A